drug
donidalorsen sodium
Marketedupdated 3mo agoby $IONS IONIS PHARMACEUTICALS INC
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Patent cliff
source: FDA Orange Bookfirst barrier falls
Oct 21, 2032
~6.2 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (5)
- May 1, 2035compositionUS 10294477
- Aug 28, 2034compositionUS 9670492
- May 1, 2034compositionUS 9127276
- May 1, 2034compositionUS 9181549
- Oct 21, 2032method-of-use (U-3010)US 9315811
News(1)
- Chiesi to buy KalVista in $1.9B deal for rare disease drugThe acquisition is the fifth of a biotech company so far this week and, according to some Wall Street analysts, proves pharma’s interest in new and emerging oral therapies for hereditary angioedema.biopharma_dive · 3mo ago
Data sources
last refreshed 6m ago
Found something off?
comments(0)
5-min edit window · permanent after that